Cue Biopharma's drug candidate CUE-101 is being tested in combination with pembrolizumab for head and neck squamous cell carcinoma.
1 report, 0 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cue Biopharma's drug candidate CUE-101 is being tested in combination with pembrolizumab for head and neck squamous cell carcinoma.
Coverage
Newest first; wire copies grouped- Unknown outlet